Education
About Us
Working with TipRanks
Follow Us
OncoTherapy Science, Inc. (DE:30O)
:30O
30O Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.09 - €0.36
Previous CloseN/A
Volume0.00
Average Volume (3M)10.00
Market Cap
€34.58M
Enterprise Value€7.94B
Total Cash (Recent Filing)€945.00M
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta-0.69
Next Earnings
Aug 01, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding275,643,700
10 Day Avg. Volume0
30 Day Avg. Volume10
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)10.59
Price to Sales (P/S)0.00
P/FCF Ratio-11.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
30O FAQ
What was OncoTherapy Science, Inc.’s price range in the past 12 months?
OncoTherapy Science, Inc. lowest stock price was €0.09 and its highest was €0.36 in the past 12 months.
What is OncoTherapy Science, Inc.’s market cap?
OncoTherapy Science, Inc.’s market cap is €34.58M.
When is OncoTherapy Science, Inc.’s upcoming earnings report date?
OncoTherapy Science, Inc.’s upcoming earnings report date is Aug 01, 2025 which is in 45 days.
How were OncoTherapy Science, Inc.’s earnings last quarter?
OncoTherapy Science, Inc. released its earnings results on Feb 07, 2025. The company reported -€0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.004.
Is OncoTherapy Science, Inc. overvalued?
According to Wall Street analysts OncoTherapy Science, Inc.’s price is currently Overvalued.
Does OncoTherapy Science, Inc. pay dividends?
OncoTherapy Science, Inc. does not currently pay dividends.
What is OncoTherapy Science, Inc.’s EPS estimate?
OncoTherapy Science, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OncoTherapy Science, Inc. have?
OncoTherapy Science, Inc. has 275,643,700 shares outstanding.
What happened to OncoTherapy Science, Inc.’s price movement after its last earnings report?
OncoTherapy Science, Inc. reported an EPS of -€0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -14.286%.
Which hedge fund is a major shareholder of OncoTherapy Science, Inc.?
Currently, no hedge funds are holding shares in DE:30O
Company Description
OncoTherapy Science, Inc.
OncoTherapy Science, Inc. researches and develops anti-cancer medicines and therapies in Japan. Its clinical development product pipeline includes small-molecule drugs, such as OTS167, a maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a T-LAK cell-originated protein kinase inhibitor for the treatment of various cancer diseases. The company's clinical development product pipeline also comprise cancer- specific peptide vaccines, including S-588410, which is in Phase III clinical trials for the treatment esophageal cancer, as well as in Phase II clinical trials for the treatment of bladder cancer; S-488210 that is in Phase I/II clinical trials for the treatment of head and neck cancer; and S-588210, which is in Phase I clinical trials for the treatment of solid tumor. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and KHK6640, an anti-amyloid beta peptide antibody that is Phase I clinical trials for Alzheimer's disease. Further, the company provides contract analysis services. OncoTherapy Science, Inc. was founded in 2001 and is headquartered in Kawasaki, Japan.
Technical Analysis
Chiome Bioscience Inc.
―
Oncolys BioPharma, Inc.
―
Healios KK
―
Delta-Fly Pharma, Inc.
―
FunPep Company Limited
―